Integration of Next-Generation Sequencing in the Surgical Management of Colorectal Liver Metastasis

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2023 Jun 14

PMID 37316745

Authors

Helen Pham

Elijah Dixon

Affiliations

Soon will be listed here.

Abstract

Hepatic resection remains the treatment of choice for colorectal liver metastases. The advancement of surgical technique and use of perioperative systemic therapy has expanded the number and complexity of patients eligible for surgical resection. In recent years, investigation into gene mutations, such as RAS/RAF pathway, have led to targeted therapies that have significantly improved outcomes. Next-generation sequencing allows analysis of large number of genes that may have potential prognostic relevance in the clinical setting. This review summarizes the current applications of next-generation sequencing technology in metastatic colorectal cancer, focusing on its prognostic implications on patient management.

References

Weitz J, Koch M, Debus J, Hohler T, Galle P, Buchler M . Colorectal cancer. Lancet. 2005; 365(9454):153-65. DOI: 10.1016/S0140-6736(05)17706-X. View

Garden O, Rees M, Poston G, Mirza D, Saunders M, Ledermann J . Guidelines for resection of colorectal cancer liver metastases. Gut. 2006; 55 Suppl 3:iii1-8. PMC: 1860000. DOI: 10.1136/gut.2006.098053. View

Ratti F, Cipriani F, Fiorentini G, Burgio V, Ronzoni M, Della Corte A . Evolution of Surgical Treatment of Colorectal Liver Metastases in the Real World: Single Center Experience in 1212 Cases. Cancers (Basel). 2021; 13(5). PMC: 7967178. DOI: 10.3390/cancers13051178. View

Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken J, Aderka D . ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8):1386-422. DOI: 10.1093/annonc/mdw235. View

Adam R, Wicherts D, de Haas R, Ciacio O, Levi F, Paule B . Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol. 2009; 27(11):1829-35. DOI: 10.1200/JCO.2008.19.9273. View

Folprecht G, Gruenberger T, Bechstein W, Raab H, Lordick F, Hartmann J . Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2009; 11(1):38-47. DOI: 10.1016/S1470-2045(09)70330-4. View

Torzilli G, Cimino M . Extending the Limits of Resection for Colorectal Liver Metastases ENHANCED ONE STAGE SURGERY. J Gastrointest Surg. 2016; 21(1):187-189. DOI: 10.1007/s11605-016-3250-8. View

Choti M, Sitzmann J, Tiburi M, Sumetchotimetha W, Rangsin R, Schulick R . Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002; 235(6):759-66. PMC: 1422504. DOI: 10.1097/00000658-200206000-00002. View

Fernandez F, Drebin J, Linehan D, Dehdashti F, Siegel B, Strasberg S . Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004; 240(3):438-47. PMC: 1356434. DOI: 10.1097/01.sla.0000138076.72547.b1. View

10.

Abdalla E, Vauthey J, Ellis L, Ellis V, Pollock R, Broglio K . Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004; 239(6):818-25. PMC: 1356290. DOI: 10.1097/01.sla.0000128305.90650.71. View

11.

van Nimwegen K, van Soest R, Veltman J, Nelen M, van der Wilt G, Vissers L . Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing. Clin Chem. 2016; 62(11):1458-1464. DOI: 10.1373/clinchem.2016.258632. View

12.

Hodges E, Xuan Z, Balija V, Kramer M, Molla M, Smith S . Genome-wide in situ exon capture for selective resequencing. Nat Genet. 2007; 39(12):1522-7. DOI: 10.1038/ng.2007.42. View

13.

Frampton G, Fichtenholtz A, Otto G, Wang K, Downing S, He J . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. PMC: 5710001. DOI: 10.1038/nbt.2696. View

14.

Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F . Next-generation sequencing: recent applications to the analysis of colorectal cancer. J Transl Med. 2017; 15(1):246. PMC: 5723063. DOI: 10.1186/s12967-017-1353-y. View

15.

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

16.

Massard C, Michiels S, Ferte C, Le Deley M, Lacroix L, Hollebecque A . High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017; 7(6):586-595. DOI: 10.1158/2159-8290.CD-16-1396. View

17.

Priestley P, Baber J, Lolkema M, Steeghs N, de Bruijn E, Shale C . Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019; 575(7781):210-216. PMC: 6872491. DOI: 10.1038/s41586-019-1689-y. View

18.

Tredan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardiere A, Fayette J . Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol. 2019; 30(5):757-765. DOI: 10.1093/annonc/mdz080. View

19.

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

20.

Janku F, Hong D, Fu S, Piha-Paul S, Naing A, Falchook G . Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014; 6(2):377-87. PMC: 4409143. DOI: 10.1016/j.celrep.2013.12.035. View